Implantica AG (IPLTF)
| Market Cap | 1.69B -18.9% |
| Revenue (ttm) | 2.82M +25.7% |
| Net Income | -22.53M |
| EPS | -0.08 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 6.24 |
| Previous Close | 6.24 |
| Day's Range | 6.24 - 6.24 |
| 52-Week Range | 4.66 - 6.77 |
| Beta | 0.78 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 19, 2026 |
About Implantica AG
Implantica AG engages in the research and distribution of medical implants in Switzerland and Spain. The company’s lead product candidate is RefluxStop, a passive CE-marked implant for prevention of gastroesophageal reflux disease. It focuses on two treatment areas, Gastrointestinal surgery and Urology. It is also involved in the development of eHealth platform, a digital health system monitor, transmit, and actively treat conditions from within the body; e-InVivo, a sensor implants to monitor a multitude of health parameters and provide diagno... [Read more]
Financial Performance
In 2025, Implantica AG's revenue was 2.07 million, an increase of 7.08% compared to the previous year's 1.94 million. Losses were -19.63 million, -15.89% less than in 2024.
Financial numbers in EUR Financial StatementsNews
Implantica's Capital Markets Day webcast available on demand
VADUZ, Liechtenstein, Sept. 11, 2026 /PRNewswire/ -- Implantica AG (publ.) would like to thank all who attended its Capital Markets Day in Stockholm on September 9, 2026.